Biometabolic outcomes after weight loss surgery: an individualized approach
NCT ID NCT04841057
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
Variable outcomes after weight loss surgery are likely attributable to complex, poorly understood mechanisms. Due to the significant impact that morbid obesity has on a patient's health, successful management of obesity and its related comorbid medical conditions is important and thus necessitates continued improved therapies for treating obesity. Although the mechanisms of weight loss after surgical intervention are poorly understood, improved understanding of molecular and metabolic changes that occur after weight loss surgery may offer the ability to provide targeted precision therapy for patients with morbid obesity undergoing surgical therapy. In this proposal, the investigators will combine a clinical trial whereby modifications to the gold-standard for weight loss surgery, the gastric bypass, are evaluated while simultaneously measuring molecular and metabolic changes that occur in response to these weight loss procedures. Through creating variable lengths of bypass intestine after gastric bypass, the investigators will be able to determine the effect of malabsorption on clinical outcomes and mechanisms involved in weight loss after gastric bypass. The investigators will also use two control groups. One will be a surgical weight loss control group and consist of patients undergoing a laparoscopic sleeve gastrectomy, a non-intestinal bypass procedure. The other group will consist of patients having non-surgical weight loss therapy. To asses metabolic changes that occur in response to surgical weight therapy and specifically intestinal bypass and malabsorption, the investigators will examine changes in the gut microbiome and plasma gut enteroendocrine hormones. To evaluate molecular pathways that are impacted as a result of gastric bypass and malabsorption, the investigators will measure circulating microRNAs (miRNAs) in the blood. Measurement of miRNAs will provide data on an easily measurable molecular marker for each treatment group. This is a first step in translational exploration of mechanisms of weight loss after surgery by evaluating both clinical and molecular/metabolic outcomes and begin an explorative process towards creating an individualized approach to improving outcomes after weight loss surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 750 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2021
- Expected to finish
-
Mar 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age greater than 18 2. Body mass index of 40-60 kg/m2 3. Meet insurance criteria, as set forth by the patient's insurance policy, to qualify for coverage for weight loss surgery 4. Planned laparoscopic Roux-en-Y gastric bypass 5. Willingness to have blood collected before and after surgical procedure at defined points and collect and mail stool sample before operation and at defined post-operative time points. Exclusion Criteria: 1. Age less than 18 2. Patient fails to fulfill insurance mandated criteria 3. Unwilling to be randomized to variable length to gastric bypass or unwilling to have blood collected or personally collect and mail in stool sample 4. Unwilling to follow-up at required postoperative visits
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Missouri-Columbia
Columbia, Missouri, 65203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Effects of very low calorie ketogenic diet on microbiota, adipose tissue and immunitary regulation: pilot study on patients with metabolic syndrome
- Longevity metrics AI/ML development study: a standing data library and Model-Development platform for predicting and validating health measurements, longevity, and disease
- A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin in patiEnts with non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM)
- Do obese children with autism face different heart risks?
- Could cutting Ultra-Processed foods reverse childhood metabolic syndrome?
- Weekly shot after gestational diabetes may shield new mothers from metabolic syndrome